Skip to content

YOD-RiSoCo: Social Cognition and Risk-taking Behaviour in Patients with Young-onset Dementia

YOD-RiSoCo: the Role of Social Cognition and Better Identification of Risk-taking Behaviour in Patients with Young-onset Dementia

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06286293
Acronym
YOD-RiSoCo
Enrollment
140
Registered
2024-02-29
Start date
2025-02-04
Completion date
2027-03-31
Last updated
2025-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Young-onset Dementia

Brief summary

The goal of this observational study is to learn about social cognition and risky behaviour in patients with young-onset dementia (YOD). The investigators want to * Examine differences in performance on social cognition test and measures of risky behaviour between behavioural variant YOD patients, patients with frontal brain injury, non-behavioural YOD patients and healthy controls. * Examine if there is a relation between social cognition tests and measures of risky behaviour. Participants will be administered a neuropsychological assessment including social cognition measures and patients will complete a driving simulator task in which risky behaviour will be elicited.

Interventions

OTHERNeuropsychological assessment, driving simulator task

Neuropsychological assessment consisting of test measuring general cognitive abilities and social cognition. Driving simulator task measuring risk-taking.

Sponsors

ZonMw: The Netherlands Organisation for Health Research and Development
CollaboratorOTHER
University Medical Center Groningen
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

All subjects * Sufficient command of the Dutch language * In possession of a driver's license with any driving experience throughout life * Age 18 to 65 bvYOD subjects * Probable diagnosis of young-onset dementia (before 65 years old), confirmed after interdisciplinary consensus meeting in which interviews, neuropsychological examination, neurological and psychiatric assessments, neuro-imaging, blood samples, and in some cases FDG/PIB-PETscans, CSF biomarkers or genetic counseling were discussed. * Nosological diagnosis of bvFTD or bvAD Non-bvYOD subjects * Probable diagnosis of young-onset dementia (before 65 years old), confirmed after interdisciplinary consensus meeting in which interviews, neuropsychological examination, neurological and psychiatric assessments, neuro-imaging, blood samples, and in some cases FDG/PIB-PETscans, CSF biomarkers or genetic counseling were discussed. * YOD subtypes other dan bvFTD or bvAD, such as amnestic variant AD. Frontal brain injury subjects \- Neurological patients with frontal brain injury (e.g. traumatic brain injury, stroke or brain tumor patients).

Exclusion criteria

All subjects * Suffering from severe motion sickness; motion sickness is a risk factor for simulator sickness YOD subjects: \- Presence of premorbid severe neurological or psychiatric pathology, non-related to dementia. Frontal brain injury subjects: \- Presence of serious psychiatric disorders or other neurological comorbidities. Healthy control subjects: * Presence of serious psychiatric disorders * History of neurological disorders, which may interfere with cognitive functioning (e.g. recent concussion, previous subarachnoid or intracerebral haemorrhage, intracranial tumours, epilepsy, ischemic stroke).

Design outcomes

Primary

MeasureTime frameDescription
Social cognitive performance2024-2027Social cognition in bvYOD, compared to non-bvYOD, patients with frontal brain injury and healthy controls

Secondary

MeasureTime frameDescription
Association between social cognition and risky decision-making2024-2027Association between several aspect of social cognition (i.e. emotion recognition, empathy, theory of mind, emotion experience) and risk-taking behaviour.

Contacts

Primary ContactGelmers
f.gelmers@umcg.nl+31 50 361 46 64

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026